Chiorean EG, Nandakumar G, Fadelu T et al (2020) Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline. JCO Glob Oncol 6:414–438

Article  PubMed  PubMed Central  Google Scholar 

Biller LH, Schrag D (2021) Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA 325:669–685

Article  CAS  PubMed  Google Scholar 

Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G (2007) From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25:1134–1143

Article  CAS  PubMed  Google Scholar 

Price TJ, Peeters M, Kim TW et al (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15:569–579

Article  CAS  PubMed  Google Scholar 

Matsuno O (2012) Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res 13:39

Article  PubMed  PubMed Central  Google Scholar 

Wygrecka M, Markart P, Ruppert C et al (2007) Cellular origin of pro-coagulant and (anti)- fibrinolytic factors in bleomycin-injured lungs. Eur Respir J 29:1105–1114

Article  CAS  PubMed  Google Scholar 

Kang S, Tanaka T, Inoue H et al (2020) IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc Natl Acad Sci U S A 117:22351–22356

Article  CAS  PubMed  PubMed Central  Google Scholar 

Douillard JY, Oliner KS, Siena S et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–1034

Article  CAS  PubMed  Google Scholar 

Arnold D, Lueza B, Douillard JY et al (2017) Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 28:1713–1729

Article  CAS  PubMed  PubMed Central  Google Scholar 

Watanabe J, Muro K, Shitara K et al (2023) Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 329:1271–1282

Article  CAS  PubMed  PubMed Central  Google Scholar 

Skeoch S, Weatherley N, Swift AJ et al (2018) Drug-induced interstitial Lung Disease: a systematic review. J Clin Med 7:356

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kudoh S, Kato H, Nishiwaki Y et al (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177:1348–1357

Article  PubMed  Google Scholar 

Yakar N, Ergun B, Ugur L et al (2021) A rare presentation of panitumumab-involved interstitial lung disease: spontaneous pneumomediastinum. J Oncol Pharm Pract 27:2061–2065

Article  PubMed  Google Scholar 

Karasu S, Sinci KA, Yildiz Y, Gumus C, Tosun O (2021) Chemotherapy-induced pulmonary toxicity mimicking COVID-19 pneumonia. Curr Med Imaging 17:1510–1512

Article  PubMed  Google Scholar 

Rezkallah KNM, Ahmed A, Patel S, Kozma K (2019) A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome. BMJ Case Rep 12:e227785

Article  PubMed  PubMed Central  Google Scholar 

Al-Asadi O, Almusarhed M, Rizvi SAJ, Saka W (2018) Fatal interstitial lung disease caused by Panitumumab-containing chemotherapy regimen. Ecancermed Sci 12:841

Google Scholar 

Yamada T, Moriwaki T, Matsuda K et al (2013) Panitumumab-induced interstitial lung disease in a case of metastatic colorectal cancer. Onkologie 36:209–212

PubMed  Google Scholar 

Yamamoto K, Kato T, Shindo J et al (2012) A case of irinotecan or panitumumab-induced interstitial pneumonia successfully treated by steroid pulse therapy. Gan To Kagaku Ryoho 39:305–309

PubMed  Google Scholar 

Osawa M, Kudoh S, Sakai F et al (2015) Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study. Int J Clin Oncol 20:1063–1071

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boku N, Sugihara K, Kitagawa Y et al (2014) Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients. Jpn J Clin Oncol 44:214–223

Article  PubMed  PubMed Central  Google Scholar 

Conte P, Ascierto PA, Patelli G et al (2022) Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open 7:100404

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takatani K, Miyazaki E, Nureki S et al (2008) High-resolution computed tomography patterns and immunopathogenetic findings in drug-induced pneumonitis. Respir Med 102:892–898

Article  PubMed  Google Scholar 

Hubbard RB, Smith C, Le Jeune I et al (2008) The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 178:1257–1261

Article  PubMed  Google Scholar 

Michael GC, Simon PH (2015) Coagulation and anticoagulation in idiopathic pulmonary fibrosis. Eur Respir Rev 24:392–399

Article  Google Scholar 

Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A (1995) Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 77:493–504

Article  CAS  PubMed  Google Scholar 

Hojyo S, Uchida M, Tanaka K et al (2020) How COVID-19 induces cytokine storm with high mortality. Inflamm Regen 40:37

Article  CAS  PubMed  PubMed Central  Google Scholar 

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group (2021) Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA 326:499–518

Article  Google Scholar